Stanford University of Palo Alto, Calif., and the Berlin-based Schering AG of the Bayer Group of Leverkusen, Germany, have entered into a joint research program to identify PET tracers for tumor imaging. Schering will have the option to assume exclusive rights to develop and commercialize such tracers, which could enable early detection of pathological changes in the body.